Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Fortress Biotech FCF Yield % Related Terms
Fortress Biotech FCF Yield % Historical Data
* Premium members only.
The historical data trend for Fortress Biotech's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CNB1 vs RLYB, INO, SEER: FCF Yield % Comparison
For the Biotechnology subindustry, Fortress Biotech's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (STU:CNB1) has a FCF Yield % of 142.72 as of Jul. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Fortress Biotech and its competitors. According to the industry distribution chart, Fortress Biotech ranks #2 out of 1409 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Fortress Biotech's FCF Yield % too high?
Fortress Biotech's current FCF Yield % is 142.72. Based on the distribution chart, Fortress Biotech ranks #2 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fortress Biotech has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's FCF Yield % compare to RLYB and INO?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #2 out of 1409 companies for FCF Yield %. This places Fortress Biotech in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current FCF Yield % is 142.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Fortress Biotech (STU:CNB1) has a current FCF Yield % of 142.72. The stock's GF Value™ is €0.73, compared to a current price of €1.93 — trading 164.4% above its estimated fair value. The current FCF Yield % is 142.72. Fortress Biotech's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Fortress Biotech (STU:CNB1), the current FCF Yield % is 142.72 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (STU:CNB1) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of €1.93 is trading 164.4% above its estimated GF Value™ of €0.73.
Key valuation signals for STU:CNB1:
FCF Yield %: 142.72
GF Value™: €0.73 vs. price of €1.93 (164.4% above fair value)
No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score
Get the complete analysis for STU:CNB1
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CNB1 has been successfully added to your 
